0.60Open0.60Pre Close0 Volume252 Open Interest9.00Strike Price0.00Turnover66.23%IV6.46%PremiumJan 17, 2025Expiry Date0.02Intrinsic Value100Multiplier23DDays to Expiry0.58Extrinsic Value100Contract SizeAmericanOptions Type-0.4660Delta0.2640Gamma14.97Leverage Ratio-0.0124Theta-0.0028Rho-6.97Eff Leverage0.0091Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet